Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) agreed to sell a total equity stake of 55% in Shanghai Fujian Equity Investment Fund Management to three parties for around 26.5 million yuan, an April 11 filing with the Hong Kong bourse said.
Of this, 29%, 25.9% and 0.1% equity interests were sold to controlling shareholder Shanghai Fosun High Technology (Group), Li Fan, and executive director Guan Xiaohui for around 14 million yuan, 12.5 million yuan, and 48,254 yuan, respectively.
Following completion, the company holds a 45% equity stake in the target company, which engages mainly in equity investment management, investment management, and investment consultancy.
The pharmaceutical firm will use proceeds from the sale for working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.